Logo

Alphamab Oncology Signs an Agreement with Sanofi for KN026

Share this

Alphamab Oncology Signs an Agreement with Sanofi for KN026

Shots:

  • Sanofi to get an exclusivity period for negotiating the in-licensing of KN026 with achievement of certain clinical milestones. The companies have initiated the enrollment for patients in the study which will evaluate KN026 +Taxotere (Docetaxel) in patients with HER2+ breast cancer
  • The focus of the agreement is to advance clinical studies to evaluate KN026 in patients with HER2 + breast cancer in China further leading to expansion of its footprints
  • Alphamab’s KN026 is an anti-HER2 bispecific Ab developed utilizing its CRIB (Charge Repulsion Induced Bispecific) a Fc-based heterodimer bispecific platform technology. In 2018- the candidate received NMPA and US FDA’s approval for IND and has shown safety- tolerance- and superior anti-tumor activity in P-I trial for HER2+ breast cancer patients progressed after multiple lines of anti-HER2 treatment

Click here to read full press release/ article | Ref: PRNewswire | Image: Signbox


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions